Today’s research is being driven by significant advances in our abilities to study complex disease processes and propose new ways to improve patients’ lives. To reflect the evolving nature of life sciences research and encourage synergies through collaboration, the Indiana Biosciences Research Institute (IBRI) is enhancing its integrated capabilities, adding depth to how it approaches patient-informed translational science and expanding its disease research to include diabetes, Alzheimer’s disease and pediatric rare diseases.

Join keynote speaker Alan Palkowitz, PhD, president and CEO of the IBRI, to learn about the IBRI’s new strategy that is built on the ambitious path that was envisioned when the IBRI was first founded in 2013. D. Wade Clapp, chairman of the department of pediatrics at the Indiana University School of Medicine, and Jay McGill, COO and executive vice president of administration for the IBRI, will join the conversation to provide examples of the IBRI’s strategy in action as it creates powerful discoveries to defeat disease.